Featured Research

from universities, journals, and other organizations

Nervous system disease: A new outlet for an old drug?

Date:
August 15, 2013
Source:
BioMed Central Limited
Summary:
A sixty-year old drug designed to treat vitamin B1 deficiency helps ease the symptoms of a chronic, progress nervous system disease, a clinical trial reveals. A large-scale, randomized controlled trial is now needed to help reveal the drugs true potential.

A sixty-year old drug designed to treat vitamin B1 deficiency helps ease the symptoms of a chronic, progress nervous system disease, a clinical trial published in the open access journal BMC Medicine reveals. A large-scale, randomised controlled trial is now needed to help reveal the drugs true potential.

The disease goes by the lengthy moniker of human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis or 'HAM/TSP' for short. It's developed by a subset of people infected with the sexually-transmitted retrovirus HTLV-1, which infects up to 20 million people worldwide, mainly in equatorial regions. The result is a chronic, progressive demyelinating disease of the lower extremities, leading to muscle weakness, spasms, paraplegia and urinary problems.

Twenty-four HAM/TSP patients, who had had the disease for up to 50 years, took the drug -- prosultiamine -- daily as part of the open-label study. Twelve weeks later, most of the patients were more mobile -- they walked more quickly and were faster at going down stairs. Bladder capacity increased and bladder problems lessened, Tatsufumi Nakamura and colleagues report.

The condition is currently managed with drugs that alter the immune response, such as corticosteroids and interferon-alpha. But their efficacy is contested, and they manage symptoms rather than cure the disease. Prosultiamine, on the other hand, reduced levels of the HTLV-1 provirus in the patients' blood, a sign that the drug may be altering the underlying pathology rather than just managing symptoms.

Results from an earlier trial suggested the drug may prove useful therapeutically, but treatment lasted just 2 weeks. Here, the drug produced favourable results with no serious adverse side effects after 3 months of treatment.

Prosultiamine is already used in the clinic to treat a couple of brain disorders induced by vitamin B1 deficiency. Studies have shown it to be safe and stable. The data presented here suggest that prosultiamine could be a promising therapeutic tool for HAM/TSP, so the next step is larger, randomised, blinded clinical trials to assess its therapeutic value.

A commentary by Jun-Ichi Kira will be published at the same time in BMC Medicine.


Story Source:

The above story is based on materials provided by BioMed Central Limited. Note: Materials may be edited for content and length.


Journal References:

  1. Tatsufumi Nakamura, Tomohiro Matsuo, Taku Fukuda, Shinji Yamato, Kentaro Yamaguchi, Ikuo Kinoshita, Toshio Matsuzaki, Yoshihiro Nishiura, Kunihiko Nagasato, Tomoko Narita-Masuda, Hideki Nakamura, Katsuya Satoh, Hitoshi Sasaki, Hideki Sakai, Atsushi Kawakami. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Medicine, 2013; 11 (1): 182 DOI: 10.1186/1741-7015-11-182
  2. Jun-Ichi Kira. Therapeutic benefits of an oral vitamin B1 derivative for HAM/TSP. BMC Medicine, 2013; 11 (1): 183 DOI: 10.1186/1741-7015-11-183

Cite This Page:

BioMed Central Limited. "Nervous system disease: A new outlet for an old drug?." ScienceDaily. ScienceDaily, 15 August 2013. <www.sciencedaily.com/releases/2013/08/130815084757.htm>.
BioMed Central Limited. (2013, August 15). Nervous system disease: A new outlet for an old drug?. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2013/08/130815084757.htm
BioMed Central Limited. "Nervous system disease: A new outlet for an old drug?." ScienceDaily. www.sciencedaily.com/releases/2013/08/130815084757.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Obama: Ebola Outbreak Threat to Global Security

Obama: Ebola Outbreak Threat to Global Security

AP (Sep. 16, 2014) President Obama is ordering U.S. military personnel to West Africa to deal with the Ebola outbreak, which is he calls a potential threat to global security. (Sept. 16) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins